STAT3 Inhibitor Trials: Analysis of 130 Oncology Studies and Development Trends

130 oncology trials targeting Signal Transducer and Activator of Transcription 3 (STAT3) were analyzed from the Trialtrove database. The dataset, authored by Siyuan Yang and last updated in May 2026, reveals trial activity peaked in 2018 and declined post-2019 due to Phase III attrition. It documents a shift from conventional SH2 domain inhibitors to next-generation strategies targeting coiled-coil domains and mitochondrial STAT3.

Use Cases

• Analyzing temporal trends in STAT3 inhibitor clinical trial activity based on the reported peak in 2018 and subsequent decline.
• Evaluating the efficacy-safety imbalance and enrollment challenges that led to Phase III attrition as described in the analysis.
• Studying the paradigm shift from Src homology 2 (SH2) domain inhibitors to next-generation strategies mentioned in the description.
• Investigating biomarker-guided patient stratification strategies for STAT3-targeted cancer therapy as discussed in the perspective.

Strengths

• Contains analysis of 130 eligible oncology trials from the Trialtrove database.
• Identifies a specific temporal trend with trial numbers peaking in 2018.
• Describes a concrete paradigm shift in inhibitor strategies from SH2 to coiled-coil and mitochondrial targeting.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (990.9 KB), indicating a limited scope of analysis.

Provenance

Source

Trialtrove database, analysis by Siyuan Yang.

Collection Method

Systematic retrospective analysis.

Time Range

Trial activity period up to 2019, with analysis noting a peak in 2018.

Freshness

Last updated 2026-05-07 04:44:59; freshness should be verified.